Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis

Genes and Development

Volumn 21, Issue 2, 2007, Pages 206-220

  Blanco, Raquel ^a   Muñoz, Purificación ^a   Flores, Juana M ^b   Klatt, Peter ^a   Blasco, María A ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cancer; Mouse models; Recombination; Telomerase; Telomeres; TRF2

Indexed keywords

TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL VIABILITY; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA DAMAGE; ENZYME DEFICIENCY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; TELOMERASE DEFICIENCY; TELOMERE; ULTRAVIOLET RADIATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANIMALS, NEWBORN; CHROMOSOMAL INSTABILITY; DISEASE MODELS, ANIMAL; DNA DAMAGE; KERATIN-5; KERATINOCYTES; MICE; RECOMBINATION, GENETIC; SKIN; SKIN NEOPLASMS; SPECIFIC PATHOGEN-FREE ORGANISMS; TELOMERASE; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 2; ULTRAVIOLET RAYS;

MUS;

EID: 33846517601     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.406207     Document Type: Article

References (51)

1. Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L., and DePinho, R.A. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406: 641-645.
2. Bailey, S.M., Brenneman, M.A., and Goodwin, E.H. 2004. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res. 32: 3743-3751.
3. Balmain, A., Ramsden, M., Bowden, G.T., and Smith, J. 1984. Activation of the mouse Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658-660.
4. Bechter, O.E., Zou, Y., Walker, W., Wright, W.E., and Shay, J.W. 2004. Telomeric recombination in mismatch repair deficient human colon cancer cells and telomerase inhibition. Cancer Res. 64: 3444-3451.
5. Biroccio, A., Rizzo, A., Elli, R., Koering, C.E., Belleville, A., Benassi, B., Leonetti, C., Stevens, M.F., D'Incalci, M., Zupi, G., et al. 2006. TRF2 inhibition triggers apoptosis and reduces tumorigenicity of human melanoma cells. Eur. J. Cancer 42: 1881-1888.
6. Blasco, M.A. 2005. Telomeres and human disease: Cancer, ageing and beyond. Nat. Rev. Genet. 6: 611-622.
7. Blasco, M.A. and Hahn, W.C. 2003. Evolving views of telomerase and cancer. Trends Cell Biol. 13: 289-294.
8. Blasco, M.A., Lee, H.-W., Hande, P., Samper, E., Lansdorp, P., DePinho, R., and Greider, C.W. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
9. Bradshaw, P.S., Stavropoulos, D.J., and Meyn, M.S. 2005. Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nat. Genet. 37: 193-197.
10. Celli, G.B. and de Lange, T. 2005. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat. Cell Biol. 7: 712-718.
11. Chan, S.W.-L. and Blackburn, E.H. 2002. New ways not to make ends meet: Telomerase, DNA damage proteins and heterochromatin. Oncogene 21: 553-563.
12. Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb, G.J., Greider, C.W., and DePinho, R.A. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97: 527-538.
13. d'Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P., Von Zglinicki, T., Saretzki, G., Carter, N.P., and Jackson, S.P. 2003. DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198.
14. Dantzer, X., Giraud-Panis, M.J., Jaco, I., Ame, J.C., Schultz, I., Blasco, M., Koering, C.E., Gilson, E., Menissier-de Murcia, J., de Murcia, G., et al. 2004. Functional interaction between poly(ADP-ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol. Cell. Biol. 24: 1595-1607.
15. de Laat, W.L., Jaspers, N.G., and Hoeijmakers, J.H. 1999. Molecular mechanism of nucleotide excision repair. Genes & Dev. 13: 768-785.
16. de Lange, T. 2002. Protection of mammalian telomeres. Oncogene 21: 532-540.
17. de Lange, T. 2005. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes & Dev. 19: 2100-2110.
18. Dlugosz, A.A., Glick, A.B., Tennenbaum, T., Weinberg, W.C., and Yuspa, S.H. 1995. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol. 254: 3-20.
19. Dunham, M.A., Neumann, A.A., Fasching, C.L., and Reddel, R.R. 2000. Telomere maintenance by recombination in human cells. Nat. Genet. 26: 447-450.
20. Garcia-Cao, M., O'Sullivan, R., Peters, A.H., Jenuwein, T., and Blasco, M.A. 2004. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36: 94-99.
21. Garcia-Cao, I., Garcia-Cao, M., Tomas-Loba, A., Martin-Caballero, J., Flores, J.M., Klatt, P., Blasco, M.A., and Serrano, M. 2006. Increased p53 activity does not accelerate telomeredriven ageing. EMBO Rep. 7: 546-552.
22. González-Suárez, E., Samper, E., Flores, J.M., and Blasco, M.A. 2000. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26: 114.
23. González-Suárez, E., Samper, E., Ramírez, A., Flores, J.M., Martín-Caballero, J., Jorcano, J.L., and Blasco, M.A. 2001. Increased epidermal tumors and increased skin, wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20: 2619-2630.
24. González-Suárez, E., Flores, J.M., and Blasco, M.A. 2002. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell. Biol. 22: 7291-7301.
25. Gonzalo, S., Jaco, I., Fraga, M.F., Chen, T., Li, E., Esteller, M., and Blasco, M.A. 2006. DNA methytransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 8: 416-424.
26. Goytisolo, F.A. and Blasco, M.A. 2002. Many ways to telomere dysfunction: In vivo studies using mouse models. Oncogene 21: 584-591.
27. Greenberg, R.A., Chin, L., Femino, A., Lee, K.H., Gottlieb, G.J., Singer, R.H., Greider, C.W., and DePinho, R.A. 1999. Short dysfunctional telomeres impair tumorigenesis in the INK4a(Δ2/3) cancer-prone mouse. Cell 97: 515-525.
28. Herrera, E., Samper, E., Martin-Caballero, J., Flores, J.M., Lee, H.W., and Blasco, M.A. 1999. Disease states associated to telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 18: 2950-2960.
29. Karlseder, J., Hoke, K., Mirzoeva, O.K., Bakkenist, C., Kastan, M.B., Petrini, J.H., and de Lange, T. 2004. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS Biol. 2: E240.
30. Laud, P.R., Multani, A.S., Bailey, S.M., Wu, L., Ma, J., Kingsley, C., Lebel, M., Pathak, S., DePinho, R.A., and Chang, S. 2005. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes & Dev. 19: 2560-2570.
31. Lee, H.-W., Blasco, M.A., Gottlieb, G.J., Greider, C.W., and De-Pinho, R.A. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature 392: 569-574.
32. Li, B., Oestreich, S., and de Lange, T. 2000. Identification of human Rap1: Implications for telomere evolution. Cell 101: 471-483.
33. Matsutani, N., Yokozaki, H., Tahara, E., Tahara, H., Kuniyasu, H., Haruma, K., Chayama, K., Yasui, W., and Tahara, E. 2001. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int. J. Oncol. 19: 507-512.
34. Modesti, M. and Kanaar, R. 2002. DNA repair: Spot(light)s on chromatin. Curr. Biol. 11: 229-232.
35. Muñoz, P., Blanco, R., Flores, J.M., and Blasco, M.A. 2005. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nat. Genet. 10: 1063-1071.
36. Muñoz, P., Blanco, R., and Blasco, M.A. 2006. Role of the TRF2 telomeric protein in cancer and ageing. Cell Cycle 5: 718-721.
37. Muntoni, A. and Reddel, R.R. 2005. The first molecular details of ALT in human tumor cells. Hum. Mol. Genet. 14: 191-196.
38. Murillas, R., Larcher, F., Conti, C.J., Santos, M., Ullrich, A., and Jorcano, J.L. 1995. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations on hair follicle development and skin structure. EMBO J. 14: 5216-5223.
39. Oh, B.-K., Kim, Y.-J., Park, C., and Park, Y.N. 2005. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am. J. Pathol. 166: 73-80.
40. Opresko, P.L., von Kobbe, C., Laine, J.P., Harrigan, J., Hickson, I.D., and Bohr, V.A. 2002. Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J. Biol. Chem. 277: 41110-41119.
41. Petit, C. and Sancar, A. 1999. Nucleotide excision repair: From E. coli to man. Biochimie 81: 15-25.
42. Samper, E., Goytisolo, F.A., Slijepcevic, P., van Buul, P.P., and Blasco, M.A. 2000. Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang. EMBO Rep. 1: 244-252.
43. Shay, J.W. and Wright, W.E. 2006. Telomerase therapeutics for cancer: Challenges and new directions. Nat. Rev. Drug Discov. 5: 577-584.
44. Smogorzewska, A., van Steensel, B., Bianchi, A., Oelmann, S., Schaefer, M.R., Schnapp, G., and de Lange, T. 2000. Control of human telomere length by TRF1 and TRF2. Mol. Cell. Biol. 20: 1659-1668.
45. Takai, H., Smogorzewska, A., and de Lange, T. 2003. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13: 1549-1556.
46. van Steensel, B., Smogorzewska, A., and de Lange, T. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell 92: 401-413.
47. Wang, R.C., Smogorzewska, A., and de Lange, T. 2004. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 119: 355-368.
48. Wu, L., Multani, A.S., He, H., Cosme-Blanco, W., Deng, Y., Deng, J.M., Bachilo, O., Pathak, S., Tahara, H., Bailey, S.M., et al. 2006. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126: 49-62.
49. Zhu, X.D., Kuster, B., Mann, M., Petrini, J.H., and Lange, T. 2000. Cell-cycle-regulated association of RAD50/MRE11/ NBS1 with TRF2 and human telomeres. Nat. Genet. 25: 347-352.
50. Zhu, X.D., Niedernhofer, L., Kuster, B., Mann, M., Hoeijmakers, J.H., and de Lange, T. 2003. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 12: 1489-1498.
51. Zijlmans, J.M., Martens, U.M., Poon, S.S., Raap, A.K., Tanke, H.J., Ward, R.K., and Lansdorp, P.M. 1997. Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc. Natl. Acad. Sci. 94: 7423-7428.